> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letters
- URL: https://www.fdaweb.com/latest-fda-warning-letters-206/
- Published: 2019-08-20T12:00:00.000Z
- Updated: 2026-09-15T01:44:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5144861

FDA has posted its latest batch of Warning Letters. They can be accessed by clicking on the link following each letter.

**Deva Holding**, Istanbul, Turkey (8/6): FDA inspected the firm in February and cited significant GMP violations for finished pharmaceuticals. For example, the company failed to perform operations related to the manufacture, processing, and packing of penicillin in facilities separate from those used for other drug products. Deva also failed to test non-penicillin drug products for the presence of penicillin when a reasonable possibility existed that the non-penicillin drug product had been exposed to cross-contamination with penicillin. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/deva-holding-cerkezkoy-subesi-577493-08062019?ref=fdaweb.com).

**Polymer Technology Systems**, Indianapolis, IN (7/31): FDA inspected the in vitro diagnostic medical devices maker in February and cited significant GMP violations. For example, the company failed to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications. It also failed to adequately validate a process whose results cannot be fully verified by subsequent inspection and test. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/polymer-technology-systems-inc-576934-07312019?ref=fdaweb.com).

**TG United**, Brooksville, FL (8/1): FDA inspected the firm in February and cited GMP violations for finished pharmaceuticals. For example, the firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications. The company also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tg-united-inc-577583-08012019?ref=fdaweb.com).